股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 醫思健康 | | | | | | 呈交日期: | 2025年12月3日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02138 | 說明 | | | | FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02138 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份 ...

Core Viewpoint - The company reported a total revenue of approximately HKD 1.931 billion for the six months ending September 30, 2025, representing a year-on-year decrease of 6.4% [1] - The company experienced a loss attributable to equity shareholders of HKD 10.312 million, marking a shift from profit to loss compared to the previous year [1] - The decline in profitability is primarily attributed to reduced revenue and sales, leading to decreased operational leverage across major business segments [1] Revenue and Profitability - Total revenue for the period was approximately HKD 1.931 billion, down 6.4% year-on-year [1] - The company reported a loss of HKD 10.312 million, with a loss per share of HKD 0.009 [1] - The decrease in profitability is linked to a shift in the service portfolio towards lower-margin categories and the absence of income from previously sold medical assets that did not contribute to profits in the same period last year [1]

Group 1 - The core viewpoint of the article is that 医思健康 (Medlive Health) reported a decline in revenue and a shift to a loss for the first half of the fiscal year ending September 30, 2025, indicating challenges in its business operations [1] Group 2 - Total revenue for the company was approximately HKD 1.931 billion, representing a year-on-year decrease of 6.4% [1] - The company reported a loss attributable to equity shareholders of HKD 10.312 million, a shift from profit to loss compared to the previous year [1] - Earnings per share were reported at a loss of HKD 0.009 [1] - The decline in profitability is primarily attributed to reduced revenue and sales, leading to decreased operational leverage across major business segments [1] - The service portfolio has shifted towards lower-margin categories, and the absence of income from previously sold medical assets, which did not contribute to profits in the same period last year, further impacted the group's profitability [1]

Core Viewpoint - The company reported a significant decline in both revenue and profit for the six months ending September 30, 2025, indicating challenges in its operational performance and market conditions [1] Financial Performance - The company recorded revenue of HKD 1.9306 billion, a year-on-year decrease of 6.4% [1] - Net profit after tax fell to HKD 4.2 million, down 89.5% compared to the previous year [1] - The loss attributable to shareholders was HKD 10.3 million, contrasting with a profit of HKD 14.1 million in the same period last year [1] Operational Challenges - The decline in profitability is primarily attributed to reduced revenue and sales, leading to lower operational leverage across major business segments [1] - The shift in service offerings towards lower-margin categories and the absence of income from previously sold medical assets further impacted profitability [1] Market Conditions - Sales amounted to HKD 1.9382 billion, representing a 7.0% decrease year-on-year [1] - Local consumer sentiment remains weak, with trends showing Hong Kong residents continuing to consume medical and wellness services in mainland China and an increase in outbound travel [1] - The strategic sale of several medical assets in the second half of the previous fiscal year negatively affected revenue performance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 對 本 公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 EC Healthcare 醫思健康 （股份代號：2138） （於開曼群島註冊成立之有限公司） 截至二零二五年九月三十日止六個月 （以 港 元 列 示） | | | | | | | | | | | | | 二零二五年 | | 二零二四年 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | 附 註 | | 千港元 | | 千港元 | | | | | | | | | | | | | | | （未 | 經 審 | 核） | （未 經 | 審 | 核） | | 收 入 | | | | | ...

Core Viewpoint - The company, Meisi Health (02138), anticipates a decline in financial performance for the six months ending September 30, 2025, compared to the same period in 2024, with significant reductions in revenue, EBITDA, and net profit. Financial Performance Summary - Revenue is expected to decrease by no more than 10% compared to approximately HKD 2.063 billion for the six months ending September 30, 2024 [1] - EBITDA is projected to decline by no more than 30% compared to approximately HKD 248 million for the same period [1] - Net profit is anticipated to drop by no more than 90% compared to approximately HKD 40.3 million for the six months ending September 30, 2024 [1] Reasons for Performance Decline - Weak local consumer sentiment, including a trend of Hong Kong residents consuming medical and healthcare services in mainland China and increased outbound travel, has weakened local demand for discretionary medical and aesthetic services [1] - Several medical assets sold in the latter half of the previous fiscal year are no longer included in the financial statements, resulting in a lack of revenue contribution during the reporting period [1] - An unfavorable service mix with a decrease in the proportion of high-margin discretionary services [1] - Revenue decline has led to weakened operational leverage [1] Financial Position Summary - The company's overall asset and liability situation remains robust, with expected cash, time deposits, and liquid financial assets totaling approximately HKD 1.1 billion at the end of the reporting period [2]

Core Viewpoint - The company, 医思健康 (02138), anticipates a decline in financial performance for the six months ending September 30, 2025, compared to the same period in 2024, with significant reductions in revenue, EBITDA, and net profit [1] Financial Performance Summary - Revenue is expected to decrease by no more than 10% from approximately HKD 2.063 billion for the corresponding period ending September 30, 2024 [1] - EBITDA is projected to decline by no more than 30% from approximately HKD 248 million for the same period [1] - Net profit is anticipated to drop by no more than 90% from approximately HKD 40.3 million for the corresponding period [1] Reasons for Decline - The board attributes the decline in net profit and EBITDA to several factors: - Weak local consumer sentiment, including a trend of Hong Kong residents consuming medical and healthcare services in mainland China, along with increased outbound travel, which has weakened local demand for discretionary medical and aesthetic services [1] - The sale of several medical assets in the latter half of the previous fiscal year, which are no longer included in the financial statements, resulting in no revenue contribution during the reporting period [1] - An unfavorable service mix, with a decrease in the proportion of high-margin discretionary services [1] - A reduction in operational leverage due to declining revenue [1] Financial Position - The board believes that the overall asset and liability situation of the company remains robust, with expected cash, time deposits, and liquid financial assets totaling approximately HKD 1.1 billion at the end of the reporting period [1]

Core Viewpoint - The company, Meisi Health (02138.HK), anticipates a decline in financial performance for the six months ending September 30, 2025, based on preliminary unaudited consolidated management accounts Group 1: Financial Performance Expectations - Revenue for the reporting period is expected to decrease by no more than 10% compared to approximately HKD 2.063 billion for the corresponding period ending September 30, 2024 [1] - EBITDA is projected to decline by no more than 30% compared to approximately HKD 247.9 million for the same period [1] - Net profit is anticipated to decrease by no more than 90% compared to approximately HKD 40.3 million for the corresponding period [1] Group 2: Reasons for Decline - Weak local consumer sentiment, including a trend of Hong Kong residents consuming medical and healthcare services in mainland China and increased outbound travel, has weakened local demand for discretionary medical and aesthetic services [1] - Certain medical assets sold in the latter half of the previous fiscal year are no longer included in the financial statements, resulting in no revenue contribution for the reporting period [1] - A less favorable service mix with a decrease in the proportion of high-margin discretionary services [1] - Declining revenue has led to weakened operating leverage [1] Group 3: Financial Position - The overall asset-liability situation of the company remains robust, with expected cash, time deposits, and liquid financial assets totaling approximately HKD 1.1 billion at the end of the reporting period [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告之全部或任何部份內容而產生或因倚賴該 等內容而引致之任 何損失承擔任何責任。 EC Healthcare 醫思健康 (i) 報告期內收入較截至 2024 年 9 月 30 日止相應期間約港幣 2,062.9 百萬元相比，減少不多 於 10%； (ii) 報告期內於扣除利息、稅項、擁有物業、廠房及設備之折舊及攤銷前盈利（「EBITDA」） 較截至 2024 年 9 月 30 日止相應期間約港幣 247.9 百萬元相比，減少不多於 30%；及 (iii) 報告期除稅後盈利（「純利」）較截至 2024 年 9 月 30 日止相應期間約港幣 40.3 百萬元相 比，減少不多於 90% 。 (於開曼群島註冊成立之有限公司) (股份代號：2138) 內幕消息 盈利警告 本公告乃由醫思健康（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合交易所有 限公司證券上市規則（「上市規則」）第 13.09 條及上市規則所指之《證券及期貨條例》（香 港法例第 571 章）（「證券及期貨條例」）第 XI ...

Core Viewpoint - The company, Meisi Health (02138.HK), announced that it will hold a board meeting on November 28, 2025, to consider and approve its interim results for the six months ending September 30, 2025, and to consider the distribution of an interim dividend, if any [1] Group 1 - The board meeting is scheduled for November 28, 2025 [1] - The meeting will focus on the interim results for the six months ending September 30, 2025 [1] - The company will also consider the potential distribution of an interim dividend [1]